Positive new data on Immune's Ceplene

Scientists from Gothenburg University, Sweden, have reported new mechanistic and tumor growth inhibition data with US biotech firm Immune Pharmaceuticals’ (Nasdaq: IMNP) Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors targeting PD-1 and PD-L1 in acute myeloid leukemia (AML), lymphoma and breast cancer models.

Immune’s shares leapt more than 31% to $0.55 in after-hours trading on Monday following the presentation of the data at the conference on "Regulatory Myeloid Suppressor Cells: From Basic Discovery to Therapeutic Application" held at the Wistar Institute in Philadelphia, PA.

Prof Kristoffer Hellstrand, laboratory chief at the Sahlgrenska Cancer Center of Gothenburg University and Ceplene inventor stated: "These in vivo results imply that Ceplene suppresses tumor growth by inhibiting NOX-2, a type of immune check point. The data also suggest that Ceplene significantly improves the anti-tumor efficacy of immune checkpoint inhibitors targeting PD-1 and PDL-1 in cancer forming the basis for the clinical development of Ceplene and other immune checkpoint inhibitors in lymphomas and solid tumors."